Pyrogen Testing Market Report 2026

The pyrogen testing market size has grown rapidly in recent years. It will grow from $1.91 billion in 2025 to $2.16 billion in 2026 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to expansion of pharmaceutical manufacturing capacity, increased production of injectable drugs and vaccines, regulatory mandates for pyrogen testing, reliance on LAL-based assays, growth of biologics development.

The pyrogen testing market size is expected to see rapid growth in the next few years. It will grow to $3.42 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to increasing adoption of rFC and MAT assays, rising investments in biopharmaceutical R&D, expansion of cell and gene therapy manufacturing, growing focus on animal-free testing solutions, increasing automation in quality control laboratories. Major trends in the forecast period include increasing adoption of recombinant and in vitro pyrogen tests, rising shift away from animal-based testing methods, growing demand for rapid and high-sensitivity detection assays, expansion of automated endotoxin testing instruments, enhanced focus on regulatory compliance in biopharmaceutical manufacturing.

The increasing investments in research and development by pharmaceutical and biotechnology companies are expected to drive the growth of the pyrogen testing market in the coming years. Pyrogen testing involves evaluating drugs and biologics to ensure they are free from fever-causing contaminants, such as endotoxins, and is essential for maintaining product safety during manufacturing. Growth in R&D spending is fueled by the need to develop advanced therapies and biologics that require strict quality control and safety assessments. Pyrogen testing supports rising R&D investments by ensuring regulatory compliance and product safety, enabling pharmaceutical and biotechnology companies to pursue innovation with greater confidence. For instance, in February 2025, according to the National Center for Science and Engineering Statistics, a US-based government statistical agency, US research and development expenditures increased from $892 billion in 2022 to $940 billion in 2023, reflecting a rise of $48 billion. Therefore, growing R&D investments by pharmaceutical companies are contributing to the expansion of the pyrogen testing market.

The rising incidence of tuberculosis is expected to further propel the growth of the pyrogen testing market going forward. Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis that primarily affects the lungs but can also spread to other organs and remains one of the leading causes of preventable deaths worldwide. The increase in TB cases is driven by factors such as population growth, urbanization, and limited access to healthcare, which result in higher infection rates among vulnerable populations. Pyrogen testing plays a critical role in pharmaceutical safety by ensuring that drugs and medical devices are free from fever-inducing contaminants such as bacterial endotoxins, thereby protecting patients. For example, in May 2025, according to the World Health Organization, a Switzerland-based health standards organization, approximately 10.8 million people developed TB globally in 2023, leading to 1.25 million deaths. These figures emphasize the growing burden of infectious diseases and the importance of stringent safety testing in pharmaceutical production. Therefore, the increasing incidence of tuberculosis is driving the growth of the pyrogen testing market.

Major companies operating in the pyrogen testing market are focusing on the development of innovative solutions such as sustainable monocyte activation test systems to expand their offerings and increase market reach. The monocyte activation test system is an in vitro assay used for pyrogen testing in the biopharmaceutical and medical device industries. For instance, in October 2023, Lonza, a Switzerland-based multinational manufacturing company, introduced two rapid monocyte activation test systems, the PyroCell MAT Rapid System and the PyroCell MAT Human Serum Rapid System. These systems, which replace Lonza’s earlier MAT kit offerings, incorporate the PeliKine Human IL-6 Rapid ELISA Kit that reduces hands-on time and shortens the time to results from two days to two hours. The new solutions provide pharmaceutical manufacturers with faster, simpler, and more efficient MAT testing options for product safety assessment while also helping to reduce reliance on animal testing.

Major companies operating in the pyrogen testing market are Thermo Fisher Scientific Inc., Merck KGaA, Charles River Laboratories Inc., Lonza Group Ltd., Ellab A S, Nelson Laboratories LLC, Associates of Cape Cod Inc., GenScript Biotech Corporation, bioMerieux SA, Hyglos GmbH, Wako Chemicals USA Inc., Pyrostar International Inc., Eurofins Scientific SE, SGS SA, WuXi AppTec Group, Sigma Aldrich Co. LLC, Bio Rad Laboratories Inc., Microcoat Biotechnologie GmbH, Sartorius AG, Pacific Biolabs Inc., Toxikon Corporation, STERIS Corporation, Avance Biosciences Inc., BioReliance Corporation, Microbiological Consulting LLC, Microbac Laboratories Inc., North American Science Associates Inc., Pace Analytical Life Sciences LLC.

North America was the largest region in the pyrogen testing market in 2025. Asia-Pacific is expected to continue to be the fastest growing region in the pyrogen testing market share during the forecast period. The regions covered in the pyrogen testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pyrogen testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the pyrogen testing market by increasing the cost of imported laboratory instruments, reagents, assay kits, and precision testing components used in LAL, in vitro, and rabbit-based testing systems. Pharmaceutical and biologics manufacturers in North America and Europe are most affected due to reliance on specialized imported testing materials, while Asia-Pacific faces higher costs in scaling quality control laboratories. These tariffs are increasing operational expenses and extending procurement timelines for testing equipment. However, they are also encouraging local reagent production, regional manufacturing of testing instruments, and innovation in cost-efficient, animal-free pyrogen testing technologies.

The pyrogen testing market research report is one of a series of new reports that provides pyrogen testing market statistics, including pyrogen testing industry global market size, regional shares, competitors with a pyrogen testing market share, detailed pyrogen testing market segments, market trends and opportunities, and any further data you may need to thrive in the pyrogen testing industry. This pyrogen testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pyrogen testing is performed to detect the presence or absence of pyrogens in all aqueous parenteral products. It is used to identify bacterial toxins in vaccines, biotechnological products, and pharmaceutical drugs that can induce fever in humans. Pyrogen testing also helps detect the presence of microorganisms and their metabolites in drugs during the manufacturing process.

The primary types of pyrogen tests include the LAL test, in vitro test, and rabbit test. The Limulus Amebocyte Lysate (LAL) test is used to detect bacterial endotoxins by utilizing amebocyte lysate derived from the Limulus crab. The rabbit pyrogen test involves injecting a small amount of the test material into a rabbit’s bloodstream and monitoring changes in the animal’s body temperature. Products used for pyrogen testing include assays, kits, reagents, instruments, and related services, and they are applied across industries such as pharmaceuticals and biologics, medical devices, and other sectors.

The pyrogen testing market includes revenues earned by entities by endotoxin testing and monocyte activation testing (MAT). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.